Status:
COMPLETED
The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults
Lead Sponsor:
University of Adelaide
Conditions:
Meningococcal Infections
Neisseria Meningitis Sepsis
Eligibility:
All Genders
15-24 years
Brief Summary
Survivors of invasive meningococcal disease (IMD) experience a range of mild to severe sequelae that impact upon their quality of life. The majority of studies to date have focused on the impact of IM...
Eligibility Criteria
Inclusion
- Patients aged 15 to 24 years 11 months at time of IMD admission
- Hospitalised IMD case from 1st January 2006 -with serogroup B or non-B IMD, confirmed by culture or polymerase chain reaction (PCR) in blood or CSF.
- Healthy controls aged 17 to 34 years 11 months at the time of assessment.
Exclusion
- Individuals who are not fluent with the English language.
- Control participants with a history of meningitis, encephalitis, or meningococcal disease, intellectual disability, intracranial pathology (eg. traumatic brain injury) that may impact on cognitive functioning, or significant vision and/or hearing loss that may impact on the validity or reliability of the neurocognitive assessment.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03798574
Start Date
March 1 2016
End Date
December 31 2022
Last Update
March 9 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital at Westmead
Westmead, New South Wales, Australia, 2145
2
Women's and Children's Hosptial
Adelaide, South Australia, Australia, 5006
3
Monash Children's Hospital, Melbourne
Clayton, Victoria, Australia, 3168
4
Perth Children's Hospital
Nedlands, Western Australia, Australia, 6009